Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2022 Mar:116:59-67.
doi: 10.1016/j.ijid.2021.12.353. Epub 2021 Dec 28.

Seroprevalence of IgG antibodies against SARS-CoV-2 in India, March 2020 to August 2021: a systematic review and meta-analysis

Nuzrath Jahan  1 , Adarsha Brahma  2 , Muthusamy Santhosh Kumar  3 , Bhavani Shankara Bagepally  1 , Manickam Ponnaiah  1 , Tarun Bhatnagar  1 , Manoj V Murhekar  1
Affiliations
Meta-Analysis

Seroprevalence of IgG antibodies against SARS-CoV-2 in India, March 2020 to August 2021: a systematic review and meta-analysis

Nuzrath Jahan et al. Int J Infect Dis. 2022 Mar.

Erratum in

Abstract

Introduction: India experienced 2 waves of COVID-19 pandemic caused by SARS-CoV-2 and reported the second highest caseload globally. Seroepidemiologic studies were done to track the course of the pandemic. We systematically reviewed and synthesized the seroprevalence of SARS-CoV-2 in the Indian population.

Methods: We included studies reporting seroprevalence of IgG antibodies against SARS-CoV-2 from March 1, 2020 to August 11, 2021 and excluded studies done only among patients with COVID-19 and vaccinated individuals. We searched published databases, preprint servers, and government documents using a combination of keywords and medical subheading (MeSH) terms of "Seroprevalence AND SARS-CoV-2 AND India". We assessed risk of bias using the Newcastle-Ottawa scale, the appraisal tool for cross-sectional studies (AXIS), the Joanna Briggs Institute (JBI) critical appraisal tool, and WHO's statement on the Reporting of Seroepidemiological Studies for SARS-CoV-2 (ROSES-S). We calculated pooled seroprevalence along with 95% Confidence Intervals (CI) during the first (March 2020 to February 2021) and second wave (March to August 2021). We also estimated seroprevalence by selected demographic characteristics.

Results: We identified 3821 studies and included 53 studies with 905379 participants after excluding duplicates, screening of titles and abstracts and full-text screening. Of the 53, 20 studies were of good quality. Some of the reviewed studies did not report adequate information on study methods (sampling = 24% (13/53); laboratory = 83% [44/53]). Studies of 'poor' quality had more than one of the following issues: unjustified sample size, nonrepresentative sample, nonclassification of nonrespondents, results unadjusted for demographics and methods insufficiently explained to enable replication. Overall pooled seroprevalence was 20.7% in the first (95% CI = 16.1 to 25.3) and 69.2% (95% CI = 64.5 to 73.8) in the second wave. Seroprevalence did not differ by age in first wave, whereas in the second, it increased with age. Seroprevalence was slightly higher among women in the second wave. In both the waves, the estimate was higher in urban than in rural areas.

Conclusion: Seroprevalence increased by 3-fold between the 2 waves of the pandemic in India. Our review highlights the need for designing and reporting studies using standard protocols.

Keywords: COVID-19; Meta-analysis; SARS-CoV-2; Seroprevalence; Systematic review.

PubMed Disclaimer

Conflict of interest statement

Competing interests Manoj V Murhekar, Tarun Bhatnagar, and Muthusamy Santhosh Kumar were part of the national COVID-19 serosurvey group and coordinated 4 rounds of serosurveys in India. These authors were not involved in the risk of bias assessment.

Figures

Figure 1
Figure 1
PRISMA flow chart of selection of studies.
Figure 2
Figure 2
Assessment of the quality of studies using The Newcastle-Ottawa Scale (NOS).
Figure 3a
Figure 3
Overall seroprevalence of SARS-CoV-2 infection during first wave (March 2020-February 2021), India.
Figure 3b
Figure 3b
Overall seroprevalence of SARS-CoV-2 infection during Second wave (March 2021-August 2021), India.
See this image and copyright information in PMC

References

    1. Alserehi HA, Alqunaibet AM, Al-Tawfiq JA, Alharbi NK, Alshukairi AN, Alanazi KH, et al. Seroprevalence of SARS-CoV-2 (COVID-19) among healthcare workers in Saudi Arabia: comparing case and control hospitals. Diagn Microbiol Infect Dis. 2021;99 doi: 10.1016/j.diagmicrobio.2020.115273. - DOI - PMC - PubMed
    1. bioRxiv.org [internet] 2021. The preprint server for Biology. https://www.biorxiv.org/
    1. Babu GR, Sundaresan R, Athreya S, Akhtar J, Pandey PK, Maroor PS, et al. The burden of active infection and anti-SARS-CoV-2 IgG antibodies in the general population: Results from a statewide survey in Karnataka. India. International Journal of Infectious Diseases. 2021;108:27–36. doi: 10.1101/2020.12.04.20243949. - DOI - PMC - PubMed
    1. Bobrovitz N, Arora RK, Cao C, Boucher E, Liu M, Donnici C, et al. Global seroprevalence of SARS-CoV-2 antibodies: A systematic review and meta-analysis. PLOS ONE. 2021;16 doi: 10.1371/journal.pone.0252617. - DOI - PMC - PubMed
    1. Bobrovitz N, Arora RK, Yan T, Rahim H, Duarte N, Boucher E, et al. Lessons from a rapid systematic review of early SARS-CoV-2 serosurveys. MedRxiv 2020:2020.05.10.20097451. 2020 doi: 10.1101/2020.05.10.20097451. - DOI